The portfolio maintains a sizable cost advantage over competitors, priced within the second-cheapest fee quintile among peers.
Fidelity Select Pharmaceuticals Port FPHAX
- NAV / 1-Day Return 29.53 / −0.14 %
- Total Assets 1.8 Bil
-
Adj. Expense Ratio
- Expense Ratio 0.700%
- Distribution Fee Level Low
- Share Class Type No Load
- Category Health
- Investment Style Large Growth
- Min. Initial Investment 0
- Status Open
- TTM Yield 0.66%
- Turnover 44%
USD | NAV as of Oct 02, 2024 | 1-Day Return as of Oct 02, 2024, 10:20 PM GMT+0
Morningstar’s Analysis FPHAX
Will FPHAX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 72.5
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 23.96 | 458.3 Mil | Healthcare |
Novo Nordisk AS ADR | 13.34 | 255.1 Mil | Healthcare |
AstraZeneca PLC ADR | 8.80 | 168.2 Mil | Healthcare |
Bristol-Myers Squibb Co | 4.96 | 94.8 Mil | Healthcare |
UCB SA | 4.75 | 90.8 Mil | Healthcare |
GSK PLC ADR | 4.49 | 85.8 Mil | Healthcare |
Merck & Co Inc | 4.22 | 80.7 Mil | Healthcare |
Gilead Sciences Inc | 3.21 | 61.4 Mil | Healthcare |
Fidelity Cash Central Fund | 3.02 | 57.8 Mil | Cash and Equivalents |
Legend Biotech Corp ADR | 2.51 | 48.0 Mil | Healthcare |